KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given an average recommendation of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $24.83.

A number of analysts recently issued reports on the company. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Jones Trading reissued a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th.

KalVista Pharmaceuticals Trading Up 2.2 %

KalVista Pharmaceuticals stock opened at $12.00 on Wednesday. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $15.50. The company has a fifty day simple moving average of $11.32 and a 200 day simple moving average of $10.33. The company has a market cap of $596.59 million, a P/E ratio of -3.30 and a beta of 0.39.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the sale, the chief executive officer now owns 287,811 shares of the company’s stock, valued at approximately $3,445,097.67. This trade represents a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the purchase, the insider now directly owns 4,986,480 shares of the company’s stock, valued at $43,681,564.80. This represents a 0.88 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 261,055 shares of company stock worth $2,397,646 and have sold 17,292 shares worth $184,625. 10.50% of the stock is owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 16.6% during the fourth quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company’s stock worth $41,613,000 after purchasing an additional 701,007 shares during the period. Tang Capital Management LLC increased its stake in KalVista Pharmaceuticals by 13.2% during the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock worth $41,451,000 after acquiring an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. increased its stake in KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock worth $41,400,000 after acquiring an additional 1,200,000 shares during the period. Vestal Point Capital LP raised its holdings in KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock valued at $40,402,000 after acquiring an additional 770,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of KalVista Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after acquiring an additional 104,716 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).